2010
DOI: 10.1378/chest.10-0134
|View full text |Cite
|
Sign up to set email alerts
|

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

50
2,812
7
152

Year Published

2011
2011
2018
2018

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 4,012 publications
(3,021 citation statements)
references
References 31 publications
50
2,812
7
152
Order By: Relevance
“…The HAS‐BLED score was calculated according to the original methods 6. Major bleeding incidence according to HAS‐BLED score, as reported in the original derivation cohort,6 is shown in Table S1.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…The HAS‐BLED score was calculated according to the original methods 6. Major bleeding incidence according to HAS‐BLED score, as reported in the original derivation cohort,6 is shown in Table S1.…”
Section: Methodsmentioning
confidence: 99%
“…Major bleeding incidence according to HAS‐BLED score, as reported in the original derivation cohort,6 is shown in Table S1. Labile international normalized ratio criterion was defined as a time in therapeutic range <65%.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…The Patient Register (http://www.sos.se) was used to obtain information needed for calculation of individual risk scores for ischaemic stroke and bleeding according to CHA 2 DS 2 ‐VASc1 and HAS‐BLED 13. In the CHA 2 DS 2 ‐VASc scheme, 2 points are given for previous stroke/transient ischaemic attack/systemic embolism, and for age ≥ 75 years and 1 point each for heart failure, hypertension, diabetes, vascular disease, female sex, and age 65–74 years.…”
Section: Methodsmentioning
confidence: 99%
“…Notably, the algorithm was updated in June of 2015 to recommend the use of the CHA 2 DS 2 –vascular disease and sex category (‐Vasc) and HAS‐BLED (defined as hemorrhage involving a critical anatomic site, for example, intracranial, or a bleed requiring hospitalization, transfusion of ≥2 units of packed cells, or associated with a decrease in hemoglobin level of ≥2 g/L) scores to estimate the patient's respective risks of embolization and bleeding, to inform shared decision making between the provider and the patient regarding the initiation of anticoagulation 20, 21. The algorithm also was updated to recommend the use of apixaban or rivaroxaban as first‐line therapy in favor of dabigatran, which was the preferential choice throughout the study period.…”
Section: Methodsmentioning
confidence: 99%